查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球藥品監管事務市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測
市場調查報告書
商品編碼
1377862

全球藥品監管事務市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測

Global Pharmaceutical Regulatory Affairs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 235 Pages | 商品交期: 最快1-2個工作天內

價格

全球藥品監管事務市場需求預計將從 2022 年的 92.3 億美元增至 2030 年近 176 億美元，2023-2030 年研究期間CAGR為 8.4%。

藥品監管事務，在製藥行業中通常簡稱為監管事務 (RA)，是一項關鍵職能，負責確保製藥和生物技術公司遵守管理開發、製造、測試、行銷和分銷的所有相關法規和法律。藥品和醫療產品。該領域在將安全有效的藥物和醫療保健產品推向市場方面發揮核心作用，同時確保它們在整個生命週期中始終符合監管標準。

市場動態：

製藥監管事務市場受到幾個關鍵因素的推動，這些因素反映了製藥業及其監管環境的動態性質。不斷變化的藥物開發和行銷規則和要求要求製藥和生物技術公司內部擁有強大的監管事務職能。藥物開發的全球化、新藥和療法的不斷出現以及對安全和品質標準的嚴格重視是關鍵促進因素。生物藥物、生物相似藥和學名藥的興起帶來了獨特的監管挑戰，需要專業知識來應對複雜的核准流程。監管事務專業人員協助適應技術進步、解決 COVID-19 大流行等全球健康問題，並確保資料透明度和合規性。醫療改革、專利到期以及以患者為中心的方法的發展進一步強調了監管事務在製藥營運中的重要性。這些因素共同強調了監管事務在指導製藥公司應對複雜的監管環境、確保藥物和療法安全、有效並符合全球多樣化和不斷發展的法規方面的關鍵作用。隨著產業不斷發展和擴張，監管事務部始終處於製藥成功和創新的最前線。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球藥品監管事務市場的各個細分市場進行了包容性評估。藥品監管事務產業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲藥品監管事務市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。藥品監管事務市場的主要參與者包括 Freyr、IQVIA Inc.、ICON plc、藥明康德、Charles River Laboratories、Labcorp Drug Development、Parexel International Corporation、Pharmalex GmbH、Pharmexon、Genpact。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第 1 章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法論
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：藥品監管事務 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按服務分類的市場吸引力分析
    • 按類別分類的市場吸引力分析
    • 按指標進行的市場吸引力分析
    • 按產品階段分類的市場吸引力分析
    • 服務提供者的市場吸引力分析
    • 按公司規模分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球藥品監理事務市場分析：依服務分類

  • 按服務概覽
  • 歷史和預測數據
  • 按服務分析
  • 監理諮詢
  • 法律代表
  • 監理寫作與出版（寫作、出版）
  • 產品註冊及臨床試驗申請
  • 其他服務

第 6 章：全球藥品監管事務市場分析：依類別

  • 按類別概述
  • 歷史和預測數據
  • 按類別分析
  • 藥物（創新藥、學名藥）
  • 生物製劑（生物技術、ATMP、生物相似藥）

第 7 章：全球藥品監理事務市場分析：依適應症分類

  • 按適應症概述
  • 歷史和預測數據
  • 按指標分析
  • 腫瘤學
  • 神經病學
  • 心臟病學
  • 免疫學
  • 其他

第 8 章：全球藥品監理事務市場分析：依產品階段

  • 按產品階段分類的概述
  • 歷史和預測數據
  • 按產品階段分析
  • 臨床前
  • 臨床研究
  • 聚甲基丙烯酸甲酯

第 9 章：全球藥品監理事務市場分析：依服務提供者分類

  • 服務提供者概覽
  • 歷史和預測數據
  • 按服務提供者分析
  • 內部
  • 外包

第 10 章：全球藥品監管事務市場分析：依公司規模

  • 按公司規模分類的概覽
  • 歷史和預測數據
  • 按公司規模分析
  • 小的
  • 中等的
  • 大的

第 11 章：全球藥品監管事務市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區國家/地區銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 12 章：藥品監理事務公司的競爭格局

  • 藥品監理事務市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 13 章：公司簡介

  • 公司股份分析
  • 市場集中度
  • Freyr
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • IQVIA Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • ICON plc
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • WuXi AppTec
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Charles River Laboratories
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Labcorp Drug Development
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Parexel International Corporation
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Pharmalex GmbH
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Pharmexon
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Genpact
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

Product Code: VMR112112255

The global demand for Pharmaceutical Regulatory Affairs Market is presumed to reach the market size of nearly USD 17.6 BN by 2030 from USD 9.23 BN in 2022 with a CAGR of 8.4% under the study period 2023 - 2030.

Pharmaceutical regulatory affairs, often simply referred to as Regulatory Affairs (RA) in the pharmaceutical industry, is a critical function responsible for ensuring that pharmaceutical and biotechnology companies comply with all relevant regulations and laws governing the development, manufacturing, testing, marketing, and distribution of drugs and medical products. This field plays a central role in bringing safe and effective medications and healthcare products to market while ensuring that they remain in compliance with regulatory standards throughout their lifecycle.

MARKET DYNAMICS:

The Pharmaceutical regulatory affairs market is propelled by several critical factors that reflect the dynamic nature of the pharmaceutical industry and its regulatory landscape. The ever-changing rules and requirements governing drug development and marketing necessitate a robust Regulatory Affairs function within pharmaceutical and biotechnology companies. Globalization of drug development, the continuous emergence of new drugs and therapies, and the stringent emphasis on safety and quality standards are key drivers. The rise of biologic drugs, biosimilars, and generic medications presents unique regulatory challenges that demand expertise in navigating complex approval processes. Regulatory Affairs professionals assist in adapting to technological advances, addressing global health concerns like the COVID-19 pandemic, and ensuring data transparency and compliance. Healthcare reforms, patent expirations, and the growth of patient-centric approaches further underscore the significance of Regulatory Affairs in pharmaceutical operations. These factors collectively underscore the critical role of Regulatory Affairs in guiding pharmaceutical companies through the intricate regulatory landscape, ensuring that drugs and therapies are safe, effective, and compliant with diverse and evolving regulations worldwide. As the industry continues to evolve and expand, Regulatory Affairs remains at the forefront of pharmaceutical success and innovation.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pharmaceutical regulatory affairs. The growth and trends of pharmaceutical regulatory affairs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pharmaceutical regulatory affairs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Services

  • Regulatory Consulting
  • Legal Representation
  • Regulatory Writing & Publishing (Writing, Publishing)
  • Product Registration & Clinical Trial Applications
  • Other Services

By Category

  • Drugs (Innovator, Generics)
  • Biologics (Biotech, ATMP, Biosimilars)

By Indication

  • Oncology
  • Neurology
  • Cardiology
  • Immunology
  • Others

By Product Stage

  • Preclinical
  • Clinical Studies
  • PMA

By Service Provider

  • In-House
  • Outsourcing

By Company Size

  • Small
  • Medium
  • Large

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Pharmaceutical Regulatory Affairs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmaceutical Regulatory Affairs market include Freyr, IQVIA Inc., ICON plc, WuXi AppTec, Charles River Laboratories, Labcorp Drug Development, Parexel International Corporation, Pharmalex GmbH, Pharmexon, Genpact. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . PHARMACEUTICAL REGULATORY AFFAIRS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Services
    • 3.7.2 Market Attractiveness Analysis By Category
    • 3.7.3 Market Attractiveness Analysis By Indication
    • 3.7.4 Market Attractiveness Analysis By Product Stage
    • 3.7.5 Market Attractiveness Analysis By Service Provider
    • 3.7.6 Market Attractiveness Analysis By Company Size
    • 3.7.7 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY SERVICES

  • 5.1 Overview by Services
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Services
  • 5.4 Regulatory Consulting Historic and Forecast Sales by Regions
  • 5.5 Legal Representation Historic and Forecast Sales by Regions
  • 5.6 Regulatory Writing & Publishing (Writing, Publishing) Historic and Forecast Sales by Regions
  • 5.7 Product Registration & Clinical Trial Applications Historic and Forecast Sales by Regions
  • 5.8 Other Services Historic and Forecast Sales by Regions

6 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY CATEGORY

  • 6.1 Overview by Category
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Category
  • 6.4 Drugs (Innovator, Generics) Historic and Forecast Sales by Regions
  • 6.5 Biologics (Biotech, ATMP, Biosimilars) Historic and Forecast Sales by Regions

7 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 Oncology Historic and Forecast Sales by Regions
  • 7.5 Neurology Historic and Forecast Sales by Regions
  • 7.6 Cardiology Historic and Forecast Sales by Regions
  • 7.7 Immunology Historic and Forecast Sales by Regions
  • 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY PRODUCT STAGE

  • 8.1 Overview by Product Stage
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Product Stage
  • 8.4 Preclinical Historic and Forecast Sales by Regions
  • 8.5 Clinical studies Historic and Forecast Sales by Regions
  • 8.6 PMA Historic and Forecast Sales by Regions

9 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY SERVICE PROVIDER

  • 9.1 Overview by Service Provider
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Service Provider
  • 9.4 In-house Historic and Forecast Sales by Regions
  • 9.5 Outsourcing Historic and Forecast Sales by Regions

10 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY COMPANY SIZE

  • 10.1 Overview by Company Size
  • 10.2 Historical and Forecast Data
  • 10.3 Analysis by Company Size
  • 10.4 Small Historic and Forecast Sales by Regions
  • 10.5 Medium Historic and Forecast Sales by Regions
  • 10.6 Large Historic and Forecast Sales by Regions

11 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY GEOGRAPHY

  • 11.1. Regional Outlook
  • 11.2. Introduction
  • 11.3. North America Sales Analysis
    • 11.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.3.2. North America By Segment Sales Analysis
    • 11.3.3. North America By Country Sales Analysis
    • 11.3.4. United State Sales Analysis
    • 11.3.5. Canada Sales Analysis
    • 11.3.6. Mexico Sales Analysis
  • 11.4. Europe Sales Analysis
    • 11.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.4.2. Europe by Segment Sales Analysis
    • 11.4.3. Europe by Country Sales Analysis
    • 11.4.4. United Kingdom Sales Analysis
    • 11.4.5. France Sales Analysis
    • 11.4.6. Germany Sales Analysis
    • 11.4.7. Italy Sales Analysis
    • 11.4.8. Russia Sales Analysis
    • 11.4.9. Rest Of Europe Sales Analysis
  • 11.5. Asia Pacific Sales Analysis
    • 11.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.5.2. Asia Pacific by Segment Sales Analysis
    • 11.5.3. Asia Pacific by Country Sales Analysis
    • 11.5.4. China Sales Analysis
    • 11.5.5. India Sales Analysis
    • 11.5.6. Japan Sales Analysis
    • 11.5.7. South Korea Sales Analysis
    • 11.5.8. Australia Sales Analysis
    • 11.5.9. South East Asia Sales Analysis
    • 11.5.10. Rest Of Asia Pacific Sales Analysis
  • 11.6. Latin America Sales Analysis
    • 11.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.6.2. Latin America by Segment Sales Analysis
    • 11.6.3. Latin America by Country Sales Analysis
    • 11.6.4. Brazil Sales Analysis
    • 11.6.5. Argentina Sales Analysis
    • 11.6.6. Peru Sales Analysis
    • 11.6.7. Chile Sales Analysis
    • 11.6.8. Rest of Latin America Sales Analysis
  • 11.7. Middle East & Africa Sales Analysis
    • 11.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.7.2. Middle East & Africa by Segment Sales Analysis
    • 11.7.3. Middle East & Africa by Country Sales Analysis
    • 11.7.4. Saudi Arabia Sales Analysis
    • 11.7.5. UAE Sales Analysis
    • 11.7.6. Israel Sales Analysis
    • 11.7.7. South Africa Sales Analysis
    • 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE PHARMACEUTICAL REGULATORY AFFAIRS COMPANIES

  • 12.1. Pharmaceutical Regulatory Affairs Market Competition
  • 12.2. Partnership/Collaboration/Agreement
  • 12.3. Merger And Acquisitions
  • 12.4. New Product Launch
  • 12.5. Other Developments

13 . COMPANY PROFILES OF PHARMACEUTICAL REGULATORY AFFAIRS INDUSTRY

  • 13.1. Company Share Analysis
  • 13.2. Market Concentration Rate
  • 13.3. Freyr
    • 13.3.1. Company Overview
    • 13.3.2. Company Revenue
    • 13.3.3. Products
    • 13.3.4. Recent Developments
  • 13.4. IQVIA Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Company Revenue
    • 13.4.3. Products
    • 13.4.4. Recent Developments
  • 13.5. ICON plc
    • 13.5.1. Company Overview
    • 13.5.2. Company Revenue
    • 13.5.3. Products
    • 13.5.4. Recent Developments
  • 13.6. WuXi AppTec
    • 13.6.1. Company Overview
    • 13.6.2. Company Revenue
    • 13.6.3. Products
    • 13.6.4. Recent Developments
  • 13.7. Charles River Laboratories
    • 13.7.1. Company Overview
    • 13.7.2. Company Revenue
    • 13.7.3. Products
    • 13.7.4. Recent Developments
  • 13.8. Labcorp Drug Development
    • 13.8.1. Company Overview
    • 13.8.2. Company Revenue
    • 13.8.3. Products
    • 13.8.4. Recent Developments
  • 13.9. Parexel International Corporation
    • 13.9.1. Company Overview
    • 13.9.2. Company Revenue
    • 13.9.3. Products
    • 13.9.4. Recent Developments
  • 13.10. Pharmalex GmbH
    • 13.10.1. Company Overview
    • 13.10.2. Company Revenue
    • 13.10.3. Products
    • 13.10.4. Recent Developments
  • 13.11. Pharmexon
    • 13.11.1. Company Overview
    • 13.11.2. Company Revenue
    • 13.11.3. Products
    • 13.11.4. Recent Developments
  • 13.12. Genpact
    • 13.12.1. Company Overview
    • 13.12.2. Company Revenue
    • 13.12.3. Products
    • 13.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Services (USD MN)
  • Regulatory Consulting Market Sales by Geography (USD MN)
  • Legal Representation Market Sales by Geography (USD MN)
  • Regulatory Writing & Publishing (Writing, Publishing) Market Sales by Geography (USD MN)
  • Product Registration & Clinical Trial Applications Market Sales by Geography (USD MN)
  • Other Services Market Sales by Geography (USD MN)
  • Analysis Market by Category (USD MN)
  • Drugs (Innovator, Generics) Market Sales by Geography (USD MN)
  • Biologics (Biotech, ATMP, Biosimilars) Market Sales by Geography (USD MN)
  • Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Cardiology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Product Stage (USD MN)
  • Preclinical Market Sales by Geography (USD MN)
  • Clinical studies Market Sales by Geography (USD MN)
  • PMA Market Sales by Geography (USD MN)
  • Analysis by Service Provider (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Outsourcing Market Sales by Geography (USD MN)
  • Analysis by Company Size (USD MN)
  • Small Market Sales by Geography (USD MN)
  • Medium Market Sales by Geography (USD MN)
  • Large Market Sales by Geography (USD MN)
  • Global Pharmaceutical Regulatory Affairs Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Pharmaceutical Regulatory Affairs Report
  • Market Research Process
  • Market Research Methodology
  • Global Pharmaceutical Regulatory Affairs Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Services
  • Market Attractiveness Analysis by Category
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Product Stage
  • Market Attractiveness Analysis by Service Provider
  • Market Attractiveness Analysis by Company Size
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Services (USD MN)
  • Regulatory Consulting Market Sales by Geography (USD MN)
  • Legal Representation Market Sales by Geography (USD MN)
  • Regulatory Writing & Publishing (Writing, Publishing) Market Sales by Geography (USD MN)
  • Product Registration & Clinical Trial Applications Market Sales by Geography (USD MN)
  • Other Services Market Sales by Geography (USD MN)
  • Global Market Analysis by Category (USD MN)
  • Drugs (Innovator, Generics) Market Sales by Geography (USD MN)
  • Biologics (Biotech, ATMP, Biosimilars) Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Cardiology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Product Stage (USD MN)
  • Preclinical Market Sales by Geography (USD MN)
  • Clinical studies Market Sales by Geography (USD MN)
  • PMA Market Sales by Geography (USD MN)
  • Global Market Analysis by Service Provider (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Outsourcing Market Sales by Geography (USD MN)
  • Global Market Analysis by Company Size (USD MN)
  • Small Market Sales by Geography (USD MN)
  • Medium Market Sales by Geography (USD MN)
  • Large Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.